Key result
Parenteral glycoprotein IIb/IIIa inhibitors improve outcomes for high-risk patients with acute coronary syndromes, whereas oral agents have not shown benefit.
Why the study?
Do glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes?
Do glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes?
Parenteral, but not oral, glycoprotein IIb/IIIa inhibitors improve clinical outcomes in patients with acute coronary syndromes, especially those at high risk or undergoing coronary intervention.
Answers are grounded in this paper and cite their sources.
Supports parenteral GP IIb/IIIa inhibitors in high-risk ACS; leaves open optimal contemporary integration and oral agent futility.
Platelet activation following the erosion or rupture of an atherosclerotic plaque is central to the development of acute coronary syndromes (ACS). Inhibition of the final common pathway of platelet aggregation using glycoprotein (GP) IIb/IIIa inhibitors has been evaluated in large-scale trials of patients with ACS. There is now consistent evidence across several trials using different parenteral GP IIb/IIIa inhibitors of improved outcomes for ACS patients treated with these agents both as primary treatment and as an adjunct to coronary intervention. The benefits particularly relate to high-risk patients. In contrast oral GP IIb/IIIa inhibitors have not been shown to improve outcomes in ACS patients.
No takes yet. Share an insight, caveat, or question.
Spence et al. (2001) conducted a review in Acute coronary syndromes (ACS). Glycoprotein (GP) IIb/IIIa inhibitors was evaluated. Parenteral glycoprotein IIb/IIIa inhibitors improve outcomes for high-risk patients with acute coronary syndromes, whereas oral agents have not shown benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: